Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: A 12-month randomized, placebo-controlled clinical trial

Journal of Rheumatology

Volumn 36, Issue 8, 2009, Pages 1705-1714

  Stoch, S Aubrey ^a   Saag, Kenneth G ^b   Greenwald, Maria ^c   Sebba, Anthony I ^d   Cohen, Stanley ^e   Verbruggen, Nadia ^a   Giezek, Hilde ^a   West, Joseph ^a   Schnitzer, Thomas J ^f  

^a MERCK RESEARCH LABORATORIES   (United States)

^b University of Alabama at Birmingham   (United States)

^c Desert Medical Advances   (United States)

^d Arthritis Associates   (United States)

^e METROPLEX CLINICAL RESEARCH CENTER   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Alendronate; Bone mineral density; Glucocorticoid; Osteoporosis; Weekly

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CARBONATE; CORTICOSTEROID; GLUCOCORTICOID; HYDROCORTISONE; METHYLPREDNISOLONE; PLACEBO; PREDNISONE; VITAMIN D;

ABDOMINAL PAIN; ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPEPSIA; FEMALE; FEMUR NECK; FRACTURE; GREATER TROCHANTER; HIP; HUMAN; HYPERTENSION; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ALENDRONATE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PLACEBOS; RHEUMATIC DISEASES; VITAMIN D;

EID: 68849106509     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.081207     Document Type: Article

References (42)

1. Shaker JL, Lukert BP. Osteoporosis associated with excess glucocorticoids. Endocrinol Metab Clin North Am 2005;34:341-56.
2. Pennisi P, Trombetti A, Rizzoli R. Glucocorticoid-induced osteoporosis and its treatment. Clin Orthop Relat Res 2006;443:39-47.
3. Liu RH, Wert VP. What is new in the treatment of steroid-induced osteoporosis? Semin Cutan Med Surg 2007;26:203-9.
4. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.
5. Steinbuch M. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporosis Int 2004;15:323-8.
6. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004;19:893-9.
7. Ettinger B, Chidambaran P, Pressman A. Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs. Am J Manag Care 2001;7:597-605.
8. Alesci S, De Martino MU, Ilias I, Gold PW, Chrousos GP. Glucocorticoid-induced osteoporosis: from basic mechanisms to clinical aspects. Neuroimmunomodulation 2005;12:1-19.
9. Canalis E. Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 2003;15:454-7.
10. Khosla S, Riggs BL. Pathophysiology of age-related bone loss and osteoporosis. Endocrinol Metab Clin North Am 2005;34:1015-30.
11. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-43.
12. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.
13. Cranney A, Wells G, Willan A, et al. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group: Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocrinol Rev 2002;23:508-16.
14. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292-9.
15. Adachi JD, Olszynski WP, Hanley DA, et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum 2000;29:228-51.
16. Lems WF, Lodder MC, Lips P, et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 2006;3:1-8.
17. Iwamoto J, Takeda T, Sato Y. Prevention and treatment of corticosteroid-induced osteoporosis. Yonsei Med J 2005;46:456-63.
18. American College of Rheumatology ad hoc committee on glucocorticoid- induced osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2001;44:1496.
19. Sambrook PN. How to prevent steroid induced osteoporosis. Ann Rheum Dis 2005;64:176-8.
20. Adler RA, Hochberg MC. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med 2003;163:2619-24.
21. Geusens PP, de Nijs RN, Lems WF, et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis 2004;63:324-5.
22. Curtis JR, Westfall AO, Allison JJ, et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 2005;52:2485-94.
23. Nawata H, Soen S, Takayanagi R, et al; The Subcommittee to Study Diagnostic Criteria for Glucocorticoid-Induced Osteoporosis. 2005 Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research. J Bone Miner Res 2004;23:105-9.
24. Blalock SJ, Norton LL, Patel RA, Dooley MA. Patient knowledge, beliefs, and behavior concerning the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2005;53:732-9.
25. Liu RH, Albrecht J, Werth VP. Cross-sectional study of bisphosphonate use in dermatology patients receiving long-term oral corticosteroid therapy. Arch Dermatol 2006;142:37-41.
26. Lozsadi DA, Peters G, Sadik HY, Kellett MW, Fox SH, Smith DF. Prevention of osteoporosis in glucocorticoid-treated neurology patients. Clin Neurol Neurosurg 2006;108:157-62.
27. Rizzoli R. Long-term outcome of weekly bisphosphonates. Clin Orthop Relat Res 2006;443:61-5.
28. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging 2000;12:1-12.
29. Luckey MM, Gilchrist N, Bone HG, et al. Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis. Obstet Gynecol 2003;101:711-21.
30. Saag KG. Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am 2003;32:135-57.
31. Devogelaer JP, Goemaere S, Boonen S, et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 2006;17:8-19.
32. Rehman Q, Lane NE. Effect of glucocorticoids on bone density. Med Pediatr Oncol 2003;41:212-6.
33. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
34. Vieth R, Bischoff-Ferrari H, Boucher BJ, et al. The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr 2007;85:649-50.
35. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003;48:3224-49.
36. Lange U, Illgner U, Teichmann J, Schleenbecker H. Skeletal benefit after one year of risedronate therapy in patients with rheumatoid arthritis and glucocorticoid-induced osteoporosis: a prospective study. Int J Clin Pharmacol Res 2004;24:33-8.
37. Sambrook PN, Kotowicz M, Nash P, et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003;18:919-24.
38. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;125:961-8.
39. de Nijs RN, Jacobs JW, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006;355:675-84.
40. Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996;313:344-6.
41. Ip M, Lam K, Yam L, Kung A, Ng M. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest 1994;10:1722-7.
42. Heffernan MP, Saag KG, Robinson JK, Callen JP. Prevention of osteoporosis associated with chronic glucocorticoid therapy. JAMA 2006;295:1300-3.